INTRODUCTION
============

The presence of sleep-disordered breathing among patients with COPD appears to be associated with an increased risk of exacerbations and with difficulty in therapeutic management.[@B1] ^,^ [@B2] Although the recommendation is that the presence of sleep-disordered breathing conditions be investigated in the history taking of such patients, these conditions frequently go unnoticed by the physician and/or the patient.[@B3]

Sleep-disordered breathing conditions such as obstructive sleep apnea (OSA) and isolated nocturnal hypoxemia (oxygen desaturation in the absence of OSA) occur in patients with COPD at a prevalence ranging from 8% to 39% and from 27% to 84%, respectively.[@B3] ^-^ [@B18] Apparently, the prevalence of sleep-disordered breathing is associated with the severity of COPD, because it has been demonstrated that subjects with COPD and an oxygen saturation less than 90% may have pronounced drops in oxygen saturation during sleep.[@B3] ^,^ [@B11] However, there is no consensus regarding the evaluation of sleep-disordered breathing in patients with COPD who have mild daytime hypoxemia (oxygen saturation between 90% and 94%).[@B4] ^,^ [@B5] ^,^ [@B19] In addition, polysomnography, a test used to diagnose OSA and nocturnal hypoxemia, is not formally indicated in this subgroup of patients with COPD, and the prevalence of these sleep-disordered breathing conditions in this subgroup is unknown.[@B4] ^,^ [@B5]

The objective of the present study was to infer the prevalence of and identify predictive variables associated with sleep-disordered breathing (OSA and isolated nocturnal hypoxemia) in patients with COPD and mild daytime hypoxemia (oxygen saturation between 90% and 94%).

METHODS
=======

Subjects, methodological design, and ethical aspects
----------------------------------------------------

This was a cross-sectional study conducted at the Clinical Research Center of the *Clínica do Aparelho Respiratório*, which is a clinic specializing in respiratory diseases, located in the city of Goiânia, Brazil.

Patients with a previous diagnosis of COPD who were not on home oxygen therapy, were clinically stable, and were ≥ 40 years of age, all of whom were admitted to the Clinical Research Center of the *Clínica do Aparelho Respiratório* between April 1 and September 31 of 2013, were considered eligible for and invited to participate in the study. After giving written informed consent, patients underwent spirometry and oximetry. Subjects who had a post-bronchodilator FEV~1~/FVC ratio \< 70; had oximetry results showing mild daytime hypoxemia (oxygen saturation between 90% and 94%); were not knowingly pregnant or had menstruated in the last 28 days (in the case of female participants); had no history of recent myocardial infarction (within three months); had no medical history of asthma or any other concomitant lung disease; had no history of cancer diagnosis; had no history of renal failure or dialysis; had no history of insulin-dependent diabetes; and had no complaints related to snoring, witnessed apneas, or excessive daytime sleepiness were included in the study. All study subjects then underwent clinical evaluation and completed validated instruments-the Medical Research Council dyspnea scale,[@B20] the COPD Assessment Test,[@B21] and a classification of socioeconomic level.[@B22] Subsequently, they underwent a six-minute walk test (6MWT), completed the Epworth Sleepiness Scale,[@B23] and underwent polysomnography, echocardiography, arterial blood gas analysis, and posteroanterior and lateral chest X-ray. Subjects with a PaO~2~ \< 60 mmHg by resting arterial blood gas analysis and/or radiographic evidence of any significant abnormality not attributable to COPD were excluded from the study. Subjects who were unable to understand or complete all instruments and interviews were also excluded. The present study was conducted in accordance with Good Clinical Practice and was approved by the Ethics Committee of the *Hospital Geral de Goiânia* (Protocol no. 198.344/2013).

Procedures and definitions
--------------------------

Clinical stability was defined as no exacerbation in the preceding four weeks.[@B24] All subjects were categorized by smoking status as smokers (subjects who were currently smoking daily or less than daily); former smokers (subjects who had smoked at least 100 cigarettes or 5 packs in their lifetime and had quit smoking); or nonsmokers (subjects who had never smoked or had smoked fewer than 100 cigarettes or 5 packs in their lifetime).[@B25]

Subjects were classified as having COPD according to the Global Initiative for Chronic Obstructive Lung Disease 2014 criteria (chronic respiratory symptoms, a history of exposure to risk factors for the disease, and a post-bronchodilator FEV~1~/FVC ratio \< 70 on spirometry).[@B2]

Nocturnal hypoxemia was defined as an oxygen saturation \< 90% for at least 5 min on polysomnography, with a nadir ≤ 85%.[@B14] Subjects were considered to have isolated nocturnal hypoxemia if their sleep study showed nocturnal hypoxemia but no OSA.[@B11]

Desaturation during the 6MWT was defined as a ≥ 4% drop in resting oxygen saturation during at least the last 3 min of the test.[@B26]

Polysomnography was performed with the Alice 5 Diagnostic Sleep System (Philips Respironics, Murrysville, PA, USA) in a sleep laboratory. Apnea was defined as airflow cessation ≥ 10 s, and hypopnea was considered present when at least one of three conditions occurred: a \> 50% reduction in airflow; a \> 50% reduction in airflow and a \> 3% drop in oxygen saturation; or a \> 50% reduction in airflow and electroencephalographic evidence of arousal. OSA was considered present when the apnea-hypopnea index (AHI) was ≥ 15 events/h (a definition aimed at being a more stringent diagnostic criterion and at reducing the possibility of overestimating the presence of OSA because of the possible presence of excessive daytime sleepiness in patients with COPD). Recordings were interpreted and sleep stages were determined according to the recommendations of the American Academy of Sleep Medicine.[@B27]

Sample size calculation
-----------------------

To calculate the sample size for the prevalence study, we estimated a proportion of the population with specific absolute accuracy by using the formula n = z^2^ ~1-α/2~P(1-P)/d^2^.[@B28] Because prevalence rates of sleep-disordered breathing demonstrate a wide range of values across studies (from 8% to 84%),[@B6] ^-^ [@B14] in the sample size calculation for the cross-sectional study, we assumed a 50% prevalence of sleep-disordered breathing as the safest choice, given that this value would yield the biggest sample size. To estimate the prevalence of sleep-disordered breathing with an absolute accuracy of 13% and a confidence level of 95%, the sample size was calculated as 57 subjects. Assuming a potential error of 10%, we decided to include at least 64 subjects in the sample.

Statistical analysis
--------------------

The results were analyzed with the STATA program, version 13.1 (StataCorp LP, College Station, TX, USA), using a level of significance of 5% (p \< 0.05). Data normality was assessed by using the Shapiro-Wilk test. Quantitative variables with normal distribution were expressed as mean and standard deviation, quantitative variables with non-normal distribution were expressed as median and interquartile range (IQR), and qualitative variables were expressed as proportions.

ANOVA was used to compare means, with Tukey's post hoc test being used to identify significant differences, whereas ANOVA with the Kruskal-Wallis post hoc test was used to compare medians. For dichotomous variables, the chi-square test or Fisher's exact test, when appropriate, was used. Logistic regression was used to calculate the odds ratios of the association between the independent or predictive variable and the outcome variable (one of the two sleep-disordered breathing conditions studied here) with 95% CIs. The cut-off value for PaO~2~ was calculated by ROC curve analysis. A correlation analysis was performed to evaluate the strength of the linear relationship between numerical variables, with Bonferroni adjustment of significance levels, and multiple linear regression was conducted to study the cause-and-effect relationship.

RESULTS
=======

[Figure 1](#f1){ref-type="fig"} shows the study population flowchart. Of the 64 subjects included in the study, 14 (21.8%) had OSA, 25 (39.1%) had isolated nocturnal hypoxemia, and 25 (39.1%) did not have either of the two sleep-disordered breathing conditions.

Figure 1Study population flowchart.

[Table 1](#t1){ref-type="table"} presents the characteristics of the study sample. All patients had mild daytime hypoxemia, according to the selection criteria of the study. The sleep-disordered breathing (OSA or isolated nocturnal hypoxemia) group did not differ from the non-sleep-disordered breathing group on any baseline characteristics, except for PaO~2~ as measured by arterial blood gas analysis, PaO~2~ being significantly lower both in the OSA group (p = 0.04) and in the isolated nocturnal hypoxemia group (p = 0.04) than in the non-sleep-disordered breathing group. However, there was no statistically significant difference in PaO~2~ between the OSA and isolated nocturnal hypoxemia groups (p = 1.00).

Table 1Characteristics of the study sample.^a^CharacteristicTotal sample (n = 64)SubgrouppOSA (n = 14)Nocturnal hypoxemia (n = 25)Non-SDB (n = 25)Age, years69.7 ± 8.869.9 ± 6.168.9 ± 9.570.4 ± 9.50.84Male gender, n (%)36 (56.3)8 (57.1)11 (44)17 (68)0.23BMI, kg/m^2^25.1 ± 5.226.9 ± 6.225.4 ± 5.923.8 ± 3.50.21Neck circumference, cm36.6 ± 4.937.8 ± 6.336.5 ± 4.035.9 ± 4.70.55Socioeconomic score17 (14-24)19 (16-24)16 (14-19)17 (13-25)0.49Smoking history, pack-years47.5 (26-60)53.3 (35-60)37 (22.5-60)51 (30-66)0.46Smokers17 (26.6)5 (35.7)9 (36)3 (12)Former smokers/never smokers47 (73.4)9 (64.3)16 (64)22 (88)0.11MAP, mmHg92.9 ± 10.595.2 ± 12.991.1 ± 9.293.3 ± 10.40.48Hypertension, n (%)^b^37 (57.8)6 (42.9)17 (68)14 (56)0.30COPD classification, n (%)GOLD A6 (9.4)2 (14.3)2 (8)2 (8)0.82GOLD B10 (15.6)2 (14.3)5 (20)3 (12)GOLD C2 (3.1)0 (0)0 (0)2 (8)GOLD D46 (71.9)10 (71.4)18 (72)18 (72)Post-BD FEV~1~, L1.29 ± 0.61.45 ± 0.51.20 ± 0.61.30 ± 0.60.45Post-BD FEV~1~, %50.2 ± 18.656.5 ± 18.448.2 ± 19.448.6 ± 17.80.36Post-BD FEV~1~/FVC, %51.3 ± 12.157.1 ± 8.849.9 ± 14.449.5 ±10.60.13PaO~2~, mmHg71.9 ± 9.869.0 ± 7.869.6 ± 9.976.0± 9.80.03\*PaCO~2~, mmHg35.1 ± 5.235.8 ± 5.936.3 ± 5.133.5 ± 4.70.15O~2~ saturation by ABG analysis, %93.8 ± 2.193.2 ± 2.193.5 ± 1.994.5 ± 2.10.11Pulmonary hypertension, n (%)3 (4.7)1 (7.1)2 (8)0 (0)Normal PASP, n (%)30 (46.9)7 (50)14 (56)9 (36)0.20Indeterminate PASP, n (%)^c^31 (48.4)6 (42.9)9 (36)16 (64)Desaturation during the 6MWT17 (26.6)4 (28.6)8 (32)5 (20)0.676MWD, % of predicted92.2 (82.4-107.7)92.4 (84.8-102.8)90.8 (82.4-107.6)92.2 (82.1-108.3)0.98CAT17 ± 7.114.4 ± 6.618 ± 6.817.4 ± 7.70.31[^1]

The median of the mean oxygen saturation as measured by oximetry during wakefulness on polysomnography was significantly lower in the OSA group (p = 0.001) and the isolated nocturnal hypoxemia group (p \< 0.0001) than in the non-sleep-disordered breathing group. However, between the OSA and isolated nocturnal hypoxemia groups, these medians were not statistically significantly different. The same results were found for mean oxygen saturation during total sleep time, during rapid eye movement (REM) sleep, and during non-REM sleep, as well as for minimum oxygen saturation, time in minutes of oxygen saturation \< 90%, and oxygen desaturation index during total sleep time, during REM sleep, and during non-REM sleep ([Figure 2](#f2){ref-type="fig"}).

Figure 2.Oxygen desaturation index during rapid eye movement (REM) sleep and non-REM sleep in the obstructive sleep apnea (OSA), isolated nocturnal hypoxemia (INH), and non-sleep-disordered breathing (SDB) groups. NS: not significant.

Sleep efficiency was reduced in all groups-OSA group: median = 70.3 and IQR: 58.5-76.5; isolated nocturnal hypoxemia group: median = 69.7 and IQR: 59.8-80.6; and non-sleep-disordered breathing group: median =70.6 and IQR: 57.1-82.9 (p = 0.89). There were no statistically significant differences in Epworth Sleepiness Scale scores among the OSA, isolated nocturnal hypoxemia, and non-sleep-disordered breathing groups (9.2 ± 4.1; 7.2 ± 4.3; and 7.3 ± 4.4, respectively; p = 0.35). The number of snoring-associated arousals was statistically higher in the OSA group than in the isolated nocturnal hypoxemia group (p = 0.001) and the non-sleep-disordered breathing group (p = 0.0001), but there was no statistically significant difference in this number between the isolated nocturnal hypoxemia and non-sleep-disordered breathing groups (p = 0.20).

Correlation analysis showed that PaO~2~ correlated moderately with mean oxygen saturation during total sleep time (r = 0.45; p = 0.0002), mean oxygen saturation during REM sleep (r = 0.43; p = 0.001), and mean oxygen saturation during non-REM sleep (r = 0.42; p = 0.001). In addition, a moderate correlation was observed between the AHI and the number of snore arousals (r = 0.53; p = 0.001). Multiple linear regression analysis was performed between the AHI as a continuous, dependent variable for OSA and clinical predictors (number of snoring-associated arousals, Epworth Sleepiness Scale score, age, body mass index, six-minute walk distance, neck circumference, oxygen saturation, PaO~2~, PaCO~2~, COPD Assessment Test score, FEV~1~, FEV~1~/FVC ratio, and mean arterial pressure), and no statistically significant coefficient was found. The same results were found using other variables as dependent variables (time in minutes of oxygen saturation \< 90% and time in minutes of oxygen saturation \< 85%, respectively, during total sleep time, during REM sleep, and during non-REM sleep) and the same clinical predictors.

When considering the baseline characteristics, the groups differed only in PaO~2~; therefore, a logistic regression analysis was conducted to determine whether PaO~2~ could independently predict sleep-disordered breathing (OR = 0.93; 95% CI: 0.87-0.99; p = 0.02). After determination of the best cut-off point to identify sleep-disordered breathing (PaO~2~ ≤ 70 mmHg), the model (OR = 4.59; 95% CI: 1.54-13.67; p = 0.01) had a specificity of 73.9% (95% CI: 51.6-89.8); a sensitivity of 63.4% (95% CI: 46.9-77.9); a positive predictive value of 81.3% (95% CI: 67.7-90.0); and a negative predictive value of 53.1% (95% CI: 41.4-64.4). The area under the ROC curve was 0.69 (95% CI: 0.57-0.80), and the proportion of correctly classified observations was 67.2%.

DISCUSSION
==========

In our study sample, 60% of the patients with COPD for whom polysomnography was not formally indicated had sleep-disordered breathing. The prevalence of nocturnal hypoxemia found in the present sample (39%) can be considered high.[@B6] ^-^ [@B14] This is because the wide variation reported in the literature (from 27% to 84%) can be explained by the use of different definitions and inclusion criteria. For instance, Chaouat et al.[@B9] used severe daytime hypoxemia (PaO~2~ \< 60 mmHg) as an inclusion criterion and found a prevalence of 70%, whereas Vos et al.[@B8] included patients with OSA and patients with central hypoventilation in the group of those with nocturnal desaturation and did not use PaO~2~ as an inclusion or exclusion criterion, finding a prevalence of 84%. Other studies have used pulse oximetry rather than polysomnography to diagnose nocturnal hypoxemia in small samples and found prevalence rates ranging from 47% to 52%.[@B10] ^,^ [@B11] ^,^ [@B13] In contrast, authors using methodologies similar to that of the present study have found similar prevalence rates.[@B7] ^,^ [@B12]

In the present study, PaO~2~ was the independent variable predictive of sleep-disordered breathing among the patients with COPD and mild daytime hypoxemia. The high positive predictive value found (81.3%) demonstrates that the cut-off point of ≤ 70 mmHg can be useful in epidemiological settings where the prevalence of sleep-disordered breathing is high, which has been demonstrated to be the usual finding.[@B8] ^-^ [@B14] A previous study showed that subjects with a resting oxygen saturation ≥ 95% seldom have isolated nocturnal hypoxemia, which suggests that the investigation of this condition is unnecessary in this subgroup of patients.[@B11] According to the current indications for the use of home oxygen therapy in COPD, patients with an oxygen saturation \< 90% (PaO~2~ \< 60 mmHg) should be evaluated and often require home oxygen therapy.[@B29] In our study sample, the subgroup of patients with COPD and daytime oxygen saturation between 90% and 94% (mild daytime hypoxemia) had a high prevalence of sleep-disordered breathing and benefited from polysomnography, although polysomnography in this context is not formally recommended by the literature. Several authors have attempted to predict nocturnal hypoxemia on the basis of patient characteristics or daytime physiological measurements.[@B6] ^,^ [@B7] ^,^ [@B10] ^-^ [@B14] However, this remains a controversial point, because although some authors have concluded that nocturnal desaturation cannot be predicted by any daytime functional measurement or anthropometric measurement, others have demonstrated that resting oxygen saturation and/or resting PaO~2~ can predict nocturnal desaturation, although not accurately (correlation coefficients of 0.51-0.78).[@B6] ^,^ [@B7] ^,^ [@B10] ^-^ [@B13] This moderate correlation and the limited prediction ability found in the present study have been confirmed by other authors, suggesting that other factors can influence oxygenation during sleep.[@B6] ^,^ [@B7] ^,^ [@B11] ^,^ [@B13] Chaouat et al.[@B9] found that a high body mass index (BMI) was associated with nocturnal desaturation, and several authors have demonstrated that a high PaCO~2~ can predict nocturnal desaturation.[@B7] ^,^ [@B11] ^,^ [@B14] The present study found no association between PaCO~2~ and nocturnal hypoxemia. This could be due to a selection bias, given that the patients in our sample had less severe COPD than did those included in other studies evaluating patients with a PaO~2~ \< 60 mmHg.[@B7] ^,^ [@B9] ^,^ [@B11] ^,^ [@B14] The same may be true for BMI. It has been demonstrated that overweight and obesity can reduce FVC and expiratory reserve volume because of the loss in baseline lung volume.[@B28] However, the subjects in the present sample had a mean BMI of 25.1 kg/m^2^, which is considered normal. Scott et al.[@B30] showed that desaturation during the 6MWT was associated with nocturnal hypoxemia (OR = 3.77, 95% CI: 1.87-7.62). Although it is possible to suggest that a lower baseline oxygen saturation may leave subjects prone to having desaturation at night and during exercise, the physiological factors related to the two conditions are different. During exercise, increased peripheral oxygen extraction, worsening of the ventilation/perfusion ratio, and dynamic hyperinflation are the causes of hypoxemia,[@B31] whereas, during sleep, reduced ventilation due to decreased responsiveness of the respiratory center, reduced accessory muscle contribution, decreased functional residual capacity, and increased closing volume, especially during REM sleep, are the factors producing hypoxemia.[@B32] The present study and two other studies also failed to demonstrate that desaturation during exercise can predict nocturnal hypoxemia.[@B10] ^,^ [@B13]

Although the prevalence of OSA found in the present study (21.8%) is within the range reported in the literature, it is higher than that reported in some studies, which is probably due to the prevalence of males and advanced age subjects in our sample, as the prevalence of OSA is higher in males and increases with age.[@B32] The relatively high prevalence of OSA found in the patients with COPD and mild hypoxemia (22%) and the reduced prevalence of clinical characteristics classically associated with OSA-systemic arterial hypertension (SAH), a high BMI, a large neck circumference, and daytime sleepiness-in this subgroup are noteworthy. The OSA group did not show a higher prevalence of SAH or have a higher level of systemic arterial pressure compared with the other groups. In addition, the results for BMI, neck circumference, and the Epworth Sleepiness Scale in the OSA group were not statistically different from those in the other groups. Venkateswaran & Tee,[@B33] in comparing COPD patients with and without OSA, also found similar results. Because of systemic inflammation, patients with COPD may have a reduction in BMI and a predisposition to SAH,[@B34] and, because of the respiratory disease, they may have decreased sleep efficiency.[@B11] Therefore, the high prevalence of SAH, the lower BMI, with a consequently smaller neck circumference, and the lower sleep efficiency observed in all groups can explain the absence of a typical clinical profile of OSA in patients with COPD.

Measurement of oxygen saturation is routinely used for the evaluation of patients with COPD because of its many advantages over blood gas analysis (it is noninvasive, painless, and inexpensive, provides immediate results, and is widely available).[@B35] In view of the findings of the present study, and in the light of the established value of oximetry as an indication for oxygen supplementation and for hospitalization in cases of acute exacerbation,[@B36] oximetry could also be used to screen patients with stable COPD for sleep-disordered breathing. When oximetry readings are between 90% and 94%, blood gas analysis could be requested. A PaO~2~ finding of ≤ 70 mmHg is associated with the presence of sleep-disordered breathing and would be an indication for requesting polysomnography.

Despite being considered the gold standard for the diagnosis of OSA syndrome, polysomnography is an expensive and technically complex test; therefore, laboratories specializing in polysomnography are scarce. To overcome this obstacle, clinical screening questionnaires should be used to identify patients at high risk for OSA, who would benefit from receiving a diagnosis and treatment as soon as possible. Studies demonstrate that portable devices have proven to be able to provide a diagnosis equivalent to that provided by in-laboratory polysomnography, at least in patients with a high likelihood of OSA.[@B37] ^,^ [@B38]

The present study has several limitations. All polysomnography tests were single-night measurements. Sleep changes associated with the initial experience of patients in a sleep laboratory are well known; therefore, in some studies, the first night is only used for acclimatizing patients. If sleep is disturbed in COPD patients, arousals may prevent deep sleep and desaturation. As a result, we could have underestimated nocturnal oxygenation by evaluating a single night's sleep. However, most studies that used polysomnography to diagnose nocturnal hypoxemia in patients with COPD made a single-night assessment,[@B6] ^,^ [@B7] ^,^ [@B9] ^,^ [@B10] ^,^ [@B13] ^,^ [@B14] and some authors have shown that there are no significant differences in mean oxygen saturation between consecutive and non-consecutive nights in the sleep laboratory.[@B35] Thus, the use of single-night polysomnography may not have affected our results. Our study was designed to assess the prevalence of sleep-disordered breathing in a subgroup of COPD patients with minor functional impairment (mild hypoxemia). The exclusion of COPD patients with moderate or severe hypoxemia may have introduced a selection bias, because patients, according to daily clinical practice, have various levels of hypoxemia, ranging from normoxemia to severe hypoxemia. In addition, for proper analysis of prevalence, there would be the need for an external control group.

In conclusion, the prevalence of sleep-disordered breathing in our sample of patients with COPD and mild hypoxemia was found to be high (61%), and a PaO~2~ finding of ≤ 70 mmHg on arterial blood gas analysis was significantly associated with sleep-disordered breathing (OR = 4.59; 95% CI: 1.54-13.67; p = 0.01). These results indicate that this subgroup of patients with COPD and mild hypoxemia would benefit from sleep studies.

Study carried out at the Centro de Pesquisa Clínica, Clínica do Aparelho Respiratório - CLARE - Goiânia (GO) Brasil.
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[^1]: OSA: obstructive sleep apnea; SDB: sleep-disordered breathing; BMI: body mass index; MAP: mean arterial pressure; GOLD: Global Initiative for Chronic Obstructive Lung Disease; BD: bronchodilator; ABG: arterial blood gas; PASP: pulmonary artery systolic pressure; 6MWT: six-minute walk test; 6MWD: six-minute walk distance; and CAT: COPD Assessment Test. ^a^Values expressed as mean ± SD or as median (interquartile range), except where otherwise indicated. ^b^Pulmonary hypertension was defined as a PASP \> 40 mmHg. ^c^Indeterminate PASP was defined as the patient having no tricuspid regurgitation.
